Kristen A Smith

US Patent:

20190389964, Dec 26, 2019

Filed:

Jun 21, 2019

Appl. No.:

16/449154

Inventors:

- San Diego CA, US
Peter Chu - San Diego CA, US
Kristen M. Smith - San Clemente CA, US
Lioudmila A. Campbell - Del Mar CA, US
Farbod Shojaei - San Diego CA, US
John Thomas Norton - San Diego CA, US

International Classification:

C07K 16/30
A61K 31/7068
A61K 31/519
A61K 31/513
A61K 31/4745
A61K 31/337
A61K 45/06
C07K 16/28
A61K 39/395

Abstract:

Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.

US Patent:

20170114145, Apr 27, 2017

Filed:

Dec 14, 2016

Appl. No.:

15/379058

Inventors:

- San Diego CA, US
Peter Chu - San Diego CA, US
Kristen M. Smith - San Clemente CA, US
Lioudmila A. Campbell - Del Mar CA, US
Farbod Shojaei - San Diego CA, US
John Thomas Norton - San Diego CA, US

International Classification:

C07K 16/30
A61K 45/06
A61K 31/337
A61K 31/519
A61K 31/513
A61K 31/4745
A61K 39/395
A61K 31/7068

Abstract:

Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.

US Patent:

20160031984, Feb 4, 2016

Filed:

Apr 2, 2015

Appl. No.:

14/677815

Inventors:

- San Diego CA, US
Peter Chu - San Diego CA, US
Kristen M. Smith - San Clemente CA, US
Lioudmila A. Campbell - Del Mar CA, US
Farbod Shojaei - San Diego CA, US
John Thomas Norton - San Diego CA, US

International Classification:

C07K 16/28
A61K 45/06
A61K 39/395

Abstract:

Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.

US Patent:

20140288087, Sep 25, 2014

Filed:

Nov 7, 2012

Appl. No.:

14/349310

Inventors:

- Oakland CA, US
Daniel Goff - La Jolla CA, US
Kristen Smith - La Jolla CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

G01N 33/574
A61K 31/506
C12Q 1/68
A61K 31/166

US Classification:

51425219, 514616, 435 612, 435 71, 435 723, 506 9

Abstract:

The disclosure provides methods for determining the self-renewal potential of a cancer stem cell (CSC), or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC. In alternative embodiments, the disclosure provides methods for determining whether a CSC in a niche is more pro-apoptotic or more anti-apoptotic in relation to a normal stem cell or a CSC from another niche. In alternative embodiments, the disclosure provides methods for determining the prognosis or malignant potential of a cancer. In alternative embodiments, the disclosure provides methods determining the anti-apoptotic versus a pro-apoptotic potential of a cancer stem cell (CSC).